Overview

A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of 0.25% HBM9036 (HL036) Ophthalmic Solution to placebo for the treatment of the Chinese subjects with moderate and severe dry eye.
Phase:
Phase 3
Details
Lead Sponsor:
Harbour BioMed (Guangzhou) Co. Ltd.
Treatments:
Ophthalmic Solutions